Hospital Avoidance Strategies for Treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
Phase of Trial: Phase IV
Latest Information Update: 07 Mar 2019
Price : $35 *
At a glance
- Drugs Dalbavancin (Primary)
- Indications Skin infections
- Focus Therapeutic Use
- 04 Mar 2019 Planned End Date changed from 1 Dec 2019 to 4 Jun 2020.
- 04 Mar 2019 Planned primary completion date changed from 1 Sep 2019 to 4 Mar 2020.
- 04 Mar 2019 Status changed from not yet recruiting to recruiting.